New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab

by Seetharamu N, Preeshagul IR, Sullivan KM
Published 2017-07-01

Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

by Kastenhuber ER, Craig J, Ramsey J, Sullivan KM, Sage J, de Oliveira S, Riehle KJ, Scott JD, Gordan JD, Bardeesy N, Abou-Alfa GK
Published 2019-01-01